According to Li et al. [168], SFN improved tamoxifen sensitivity via epigenetic reactivation of ER in ER-negative BrCa, according to researchers who conducted the studies, both in vitro and in vivo. The gene discussed is ESR1; the disease is invasive breast carcinoma.